.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Fish and Richardson
Chinese Patent Office
Moodys
Chubb
Julphar
Teva
Accenture
Federal Trade Commission
Daiichi Sankyo

Generated: December 17, 2017

DrugPatentWatch Database Preview

Patents Expiring in 2030

« Back to Dashboard

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Salix PharmsRELISTORmethylnaltrexone bromideSOLUTION;SUBCUTANEOUS021964-003Sep 27, 2010RXYesYes► Subscribe► SubscribeTREATMENT OF OPIOID-INDUCED CONSTIPATION
Salix PharmsRELISTORmethylnaltrexone bromideSOLUTION;SUBCUTANEOUS021964-001Apr 24, 2008RXYesYes► Subscribe► SubscribeTREATMENT OF OPIOID-INDUCED CONSTIPATION
Salix PharmsRELISTORmethylnaltrexone bromideSOLUTION;SUBCUTANEOUS021964-002Sep 27, 2010RXYesYes► Subscribe► SubscribeTREATMENT OF OPIOID-INDUCED CONSTIPATION
Cubist Pharms LlcSIVEXTROtedizolid phosphateTABLET;ORAL205435-001Jun 20, 2014RXYesYes► Subscribe► SubscribeYYMETHOD OF TREATING BACTERIAL INFECTIONS
Cubist Pharms LlcSIVEXTROtedizolid phosphatePOWDER;IV (INFUSION)205436-001Jun 20, 2014RXYesYes► Subscribe► SubscribeYYMETHOD OF TREATING BACTERIAL INFECTIONS
Sanofi-aventis UsADLYXINlixisenatideSOLUTION;SUBCUTANEOUS208471-002Jul 27, 2016RXYesYes► Subscribe► SubscribeYIMPROVEMENT IN GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR
Sanofi-aventis UsADLYXINlixisenatideSOLUTION;SUBCUTANEOUS208471-002Jul 27, 2016RXYesYes► Subscribe► SubscribeYIMPROVEMENT IN GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR
Sanofi-aventis UsADLYXINlixisenatideSOLUTION;SUBCUTANEOUS208471-001Jul 27, 2016RXYesYes► Subscribe► SubscribeYIMPROVEMENT IN GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR
Sanofi-aventis UsADLYXINlixisenatideSOLUTION;SUBCUTANEOUS208471-001Jul 27, 2016RXYesYes► Subscribe► SubscribeYIMPROVEMENT IN GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR
Portola Pharms IncBEVYXXAbetrixabanCAPSULE;ORAL208383-002Jun 23, 2017RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Teva
US Department of Justice
Baxter
US Army
Mallinckrodt
Dow
Chubb
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot